The 563-patient blinded study found that HearO predicted more than 70% of heart failure events at an average of 24.6 days before they occurred, with high patient compliance and no device-related adverse events.
The 563-patient blinded study found that HearO predicted more than 70% of heart failure events at an average of 24.6 days before they occurred, with high patient compliance and no device-related adverse events.
Amgen announced results from a large real-world study showing that treatment with Repatha® (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe in people with atherosclerotic cardiovascular disease...
Amgen announced results from a large real-world study showing that treatment with Repatha® (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe in people with atherosclerotic cardiovascular disease...
Compared with usual care based on stress testing, care guided by AI-based quantitative coronary CT analysis (AI-QCT) improved diagnostic certainty and led to more patients receiving lipid-lowering therapy.
Compared with usual care based on stress testing, care guided by AI-based quantitative coronary CT analysis (AI-QCT) improved diagnostic certainty and led to more patients receiving lipid-lowering therapy.
Patients with acute myocardial infarction complicated by cardiogenic shock who received intravenous cangrelor had less microvascular obstruction and greater recovery of left ventricular function than those receiving crushed oral ticagrelor,...
Patients with acute myocardial infarction complicated by cardiogenic shock who received intravenous cangrelor had less microvascular obstruction and greater recovery of left ventricular function than those receiving crushed oral ticagrelor,...
Sub-analysis presented at TCT 2026 shows substantial clot burden reduction and improved right-heart function with the Symphony Thrombectomy System despite greater baseline cardiac stress in women
Sub-analysis presented at TCT 2026 shows substantial clot burden reduction and improved right-heart function with the Symphony Thrombectomy System despite greater baseline cardiac stress in women
Nearly nine out of 10 patients experienced a clinical benefit at six months. Medtronic receives FDA approval for U.S. labeling update to Symplicity blood pressure procedure, expanding clinical evidence informing treatment options
Nearly nine out of 10 patients experienced a clinical benefit at six months. Medtronic receives FDA approval for U.S. labeling update to Symplicity blood pressure procedure, expanding clinical evidence informing treatment options
Annual TAVR procedures among patients younger than 70 rose from 15 in 2014 to 134 in 2024 within one health system, driven primarily by patients in their 60s, while surgery remained predominant.
Annual TAVR procedures among patients younger than 70 rose from 15 in 2014 to 134 in 2024 within one health system, driven primarily by patients in their 60s, while surgery remained predominant.
